- Home
- EW vs TAK Comparison
EW vs TAK Comparison
Compare EW & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EW | TAK |
|---|---|---|
| Founded | 1958 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2B | 52.4B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | EW | TAK |
|---|---|---|
| Price | $86.24 | $15.95 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $96.37 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 3.1M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $6,067,600,000.00 | N/A |
| Revenue This Year | $13.39 | $0.16 |
| Revenue Next Year | $9.81 | $1.22 |
| P/E Ratio | $130.13 | ★ $41.25 |
| Revenue Growth | ★ 11.55 | N/A |
| 52 Week Low | $72.30 | $12.99 |
| 52 Week High | $88.28 | $18.90 |
Technical Indicators
Market Signals| Indicator | EW | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 33.75 |
| Support Level | $81.39 | $15.88 |
| Resistance Level | $86.95 | $16.48 |
| Average True Range (ATR) | 2.40 | 0.23 |
| MACD | 0.52 | -0.01 |
| Stochastic Oscillator | 82.70 | 11.96 |
Price Performance
Historical ComparisonAbout EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.